Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms

Key Points. Exposure to thalidomide analogs, particularly lenalidomide, is associated with increased risk of TP53-mutated myeloid neoplasmsTreatment with lenali

Read the full article here

Related Articles